(Nasdaq: TLSA) Triggers Friday's Early AM Radar (Huge News This Week And A Boosted Analyst Target)

We're on a heater this week.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: TLSA) Triggers Friday's Early AM Radar (Huge News This Week And A Boosted Analyst Target) *Click Here To Get Our Alerts Faster Via SMS* May 22nd Greetings Readers, We're on a heater this week. In fact, Thursday's profile showed off in a major way. Surging to a high of $5.36 after closing the previous day at $4.43, that Nasdaq idea popped vertically quickly. All in all, the short term run resulted in a move of approx. 20%. That comes on the heels of a 2-day runner that moved to a new 3+ month high of $1.70 on Thursday following Tuesday's close of $1.26. When the dust settled, that short term move of approx. 34% confirmed another breakout star. With breakthroughs in neurodegenerative disease treatment accelerating, one under-the-radar company has popped up on our radar with the Alzheimer’s therapy market is projected to exceed $15Bn by 2030 and multiple sclerosis treatments expected to surpass $35Bn globally. And following two key developments this week (boosted analyst target and a "pivotal" company moment), this Nasdaq idea is topping our watchlist Friday: Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) Tiziana is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. The Company's innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. And based on several potential catalysts, (Nasdaq: TLSA) has taken over the top spot on my watchlist. Check them out: #1. A Major News Announcement This Week Represents A "Pivotal Moment" For The Company. #2. An Analyst $9 Target Suggests Triple-Digit Potential Upside From Current Chart Levels. #3. Announced Positive Clinical Data Demonstrate Foralumab Continues To Be Extremely Well Tolerated Over Extended Treatment Durations. #4. The Company's Phase 2 Clinical Trial For Foralumab Shows Marked Reduction In Inflammation On PET Scans. #5. More Positive Data Announced In A Key Publication (Supports Therapeutic Potential Of Lead Candidate). But more on those in a second... Tiziana Life Science Full Company Breakdown Tiziana Life Sciences is a clinical stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and neuroinflammatory. Their clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer’s, and ALS. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience. Company Background Tiziana's mission is to design and deliver next generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The Company's lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Foralumab is the only fully human anti-CD3 monoclonal antibody under clinical development and is expected to minimize adverse immune responses in patients. Tiziana has submitted a patent application on potential use of Foralumab, to improve success of chimeric antigen receptor T cells (CAR-T) therapy for cancer and other human diseases. The patent application covers inventions related to improving CAR-T expansion and/or survival. The Company employs a lean and virtual research and development model using highly experienced teams of experts for each business function to maximize value accretion by focusing resources on the drug discovery and development processes. Corporate Strategy -- Continue the clinical development of intranasal administration of Foralumab for neurodegenerative disease indications: Secondary Progressive, Multiple Sclerosis Alzheimer’s Amyotrophic Lateral Sclerosis (ALS) -- Commence Phase 2 clinical trial after successfully receiving their Investigational New Drug Application (IND) to conduct a Phase 2 study intranasal foralumab in Alzheimer’s disease patients. -- Submit an Investigational New Drug Application (IND) to conduct a Phase 2 study intranasal foralumab in Alzheimer’s disease patients. -- Seek orphan drugs fast track or breakthrough designation for the Company's product candidates where warranted. Intranasal Foralumab Pipeline Grab Sources And More: TLSA Website. TLSA Presentation. ----- And as I mentioned previously, (Nasdaq: TLSA) has several potential catalysts we're tracking. Check them out:  #1. TLSA Potential Catalyst - A Major News Announcement This Week Represents A "Pivotal Moment" For The Company. Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that patient enrollment has been completed in its randomized, double-blind, placebo-controlled Phase 2a clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Topline data is expected in late Q3 of 2026, and will also to be presented at the 10th joint Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and ECTRIMS meeting in Toronto, Canada in October 2026. The trial (NCT06292923), known as INFORM-MS, is the first Phase 2 placebo-controlled study of intranasal foralumab, marking a significant milestone in the clinical development of this novel anti-CD3 monoclonal antibody for neurodegenerative and neuroinflammatory diseases. The multicenter study has enrolled 48 patients across multiple leading U.S. sites to receive one of two doses of intranasal foralumab or placebo over a 12-week treatment period, with assessments including PET imaging for microglial activation, MRI, clinical evaluations, and biomarkers. Following the completion of the blinded phase, all participants including those who initially received placebo will have the opportunity to receive intranasal foralumab during a six-month open label extension (OLE) phase. The OLE is designed to assess long term safety and sustained benefit of foralumab in the na-SPMS patient population. “This completion of enrollment in our Phase 2a trial represents a pivotal moment for Tiziana Life Sciences and for patients suffering from na-SPMS, a condition with limited treatment options,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “As the first placebo-controlled trial of intranasal foralumab, this study underscores our commitment to rigorously evaluating this innovative therapy’s potential to modulate the immune system and address neuroinflammation. We are grateful for the dedication of our clinical partners and look forward to sharing topline results that could pave the way for a new treatment paradigm.” ... Read the full article here. ----- #2. TLSA Potential Catalyst - An Analyst $9 Target Suggests Triple-Digit Potential Upside From Current Chart Levels. This week, Lucid Capital Markets provided a key update on TLSA. In the update, Lucid reiterated an $9.00 target on TLSA. From Thursay's close, that target represents a potential 475+% upside. Report highlights: Tiziana Life Sciences (TLSA) reported long-term data from its multiple sclerosis expanded access program, indicating disease stabilization and reduction in fatigue, along with initial PET imaging data from a novel indication: Multiple System Atrophy (MSA). We are increasingly confident on the potential success of foralumab in multiple neuroinflammatory conditions. Therefore, ..., but increase our 12-month price target from $8 to $9/share. ----- #3. TLSA Potential Catalyst - Announced Positive Clinical Data Demonstrate Foralumab Continues To Be Extremely Well Tolerated Over Extended Treatment Durations. Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Favourable trends seen in stability of disability and clinically meaningful improvements in fatigue. BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces updated clinical data from its ongoing Expanded Access ("EA") Program evaluating intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The data, updated from March 2025 to as of March 2026, demonstrate that intranasal foralumab continues to be extremely well tolerated over extended treatment durations. Patients showed encouraging trends in stabilization of disability as measured by the Expanded Disability Status Scale (EDSS) and meaningful improvements in fatigue as measured by the Modified Fatigue Impact Scale (MFIS). ... Dr. Howard L. Weiner, Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital, and Chair of the Scientific Advisory Board of Tiziana Life Sciences, commented: "These longer-term results from the Expanded Access SPMS Program continue to support the potential of intranasal foralumab as a novel, immunomodulatory therapy for patients with non-active SPMS. The excellent tolerability profile combined with trends toward disability stabilization and fatigue improvement is highly encouraging and warrants further investigation." Ivor Elrifi, CEO of Tiziana Life Sciences, added: "We are pleased with the continued positive safety and clinical trend data from our Expanded Access Program. Intranasal foralumab's unique mechanism, which reduces neuroinflammation, positions it as a potential new treatment paradigm for progressive forms of multiple sclerosis where treatment options remain limited. We look forward to advancing this program to approval." Read the full article here. ----- #4. TLSA Potential Catalyst - The Company's Phase 2 Clinical Trial For Foralumab Shows Marked Reduction In Inflammation On PET Scans. Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab Foralumab is the first intranasal immune modulator in clinical trials for patients with Multiple System Atrophy BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial quantitative PET imaging results from the first two patients with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab. This is the third indication that has shown a marked reduction in inflammation on PET scans following treatment with intranasal foralumab. Quantitative analysis of PET scans demonstrated reductions in inflammatory activity in clinically relevant brain regions known to be affected in MSA following treatment with intranasal foralumab. In the first two treated patients, investigators observed up to approximately 35% reduction in standardized uptake value (SUV) and approximately 24% reduction in standardized uptake value ratio (SUVR) in affected areas of the brain. ... “These early PET imaging findings provide quantitative evidence supporting the biological activity of intranasal foralumab in patients with MSA,” said Tarun Singhal, MBBS, M.D., Founding Director, NeuroPET Program, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Mass General Brigham. “In the first two MSA patients we evaluated, we observed up to approximately 35% reduction in standardized uptake value and a 24% reduction in SUV ratio in the affected brain regions. We focused on the most severely affected, clinically relevant areas known to be involved in MSA. Based on the available data, these appear to be robust quantitative findings and are comparable to results previously observed in patients with multiple sclerosis treated with intranasal foralumab, although there are methodological differences.” “This is the third indication that we have seen a marked reduction in inflammation on PET scans following treatment with intranasal foralumab,” said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. “Building on the encouraging results previously reported in non-active secondary progressive multiple sclerosis and moderate Alzheimer’s disease, these initial MSA data further highlight the potential of our therapy to meaningfully address neuroinflammation across multiple neurodegenerative conditions with high unmet need.” ... Read the full article here. ----- #5. TLSA Potential Catalyst - More Positive Data Announced In A Key Publication (Supports Therapeutic Potential Of Lead Candidate). Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long CVD Neuroinflammation and Improves Cognitive Function Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long CVD associated “brain fog." BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the publication of positive preclinical data in a bioRxiv preprint. The study, titled “Intranasal Anti-CD3 Antibody Treatment Attenuates Post CVD Neuroinflammation and Enhances Hippocampal Neurogenesis and Cognitive Function in Mice,” demonstrates that nasal anti-CD3 treatment significantly reduces neuroinflammation, boosts regulatory T cells (Tregs) in the brain, restores hippocampal neurogenesis, and improves short-term memory in a model of Long CVD. ... These findings show that nasal anti-CD3 can potently induce regulatory T cells that cross into the brain and dampen persistent neuroinflammation triggered by even mild respiratory viral infection. By reprogramming microglia, reducing harmful chemokines like CCL11, and restoring the hippocampal neurogenic niche, this approach offers a promising, non-invasive strategy to address the cognitive impairment often called ‘brain fog’ that continues to affect millions of Long CVD patients worldwide. ... Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences, commented: “We are thrilled to see these robust preclinical data in BioRxiv, further validating the broad therapeutic potential of our intranasal foralumab platform. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development, and these results directly support the mechanistic foundation for our ongoing programs in non active secondary progressive multiple sclerosis, MSA, Alzheimer’s disease, and ALS.” ... Read the full article here. ----- (Nasdaq: TLSA) Recap - 5 Potential Catalysts On Our Radar #1. A Major News Announcement This Week Represents A "Pivotal Moment" For The Company. #2. An Analyst $9 Target Suggests Triple-Digit Potential Upside From Current Chart Levels. #3. Announced Positive Clinical Data Demonstrate Foralumab Continues To Be Extremely Well Tolerated Over Extended Treatment Durations. #4. The Company's Phase 2 Clinical Trial For Foralumab Shows Marked Reduction In Inflammation On PET Scans. #5. More Positive Data Announced In A Key Publication (Supports Therapeutic Potential Of Lead Candidate). ----- Coverage is officially underway on Tiziana Life Sciences, Ltd. (Nasdaq: TLSA). Updates will be coming down the wire soon. Talk shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 05/22/2026 and ending on 05/22/2026 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid thirty five thousand USD ("Funds"). These Funds were part of the forty seven thousand five hundred USD funds that TD Media LLC received from a third party named Sica Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (TLSA:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/tlsa-vconj/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice